Anil R Diwan PhD

President & Chairman
NanoViricides, Inc.
(NYSEAMERICAN: NNVC)

Dr. Anil R. Diwan is the President and Chairman of NanoViricides, Inc. He has 30+ years of experience in the design, synthesis and characterization of nanomedicines. He invented “TheraCour┬«” nanomedicines technologies circa 1992 at AllExcel, Inc., a private company he founded. The TheraCour technologies form the basis of the nanoviricides┬« platform technologies.

Dr. Diwan co-founded NanoViricides, Inc. that was taken public via a reverse shell merger in 2005, and became a reporting company trading on OTC-BB in 2007. He led its up-listing to the NYSE MKT (now American) exchange in September 2013, where the Company trades under the symbol NNVC. Dr. Diwan has also played a lead role in raising over $70M. He developed a cGMP-capable injectables manufacturing suite and a state of the art nanomedicines characterization R&D laboratory by raising private financing on his own, and also played a key role in the design, architecture, and set-up of the facility. This facility was later purchased at cost by NanoViricides, and is now the NanoViricides campus in Shelton, CT. He is intimately involved day-to-day in all of the drug development activities, from design and synthesis to characterization and testing.

Prior to founding AllExcel, Inc., Dr. Diwan performed post-doctoral research in Virology and Biophysics at the University of Connecticut, Storrs, CT. Before that, he did post-doctoral research in Biomedical Engineering at the University of Wisconsin, Madison, WI. He holds a Ph.D. in Biochemical Engineering from Rice University, and a B.Tech. in Chemical Engineering from IIT Bombay.